Roche Eyes Adjuvant HCC Setting After Phase III Tecentriq Combination Success
But Market Opportunity Limited
The firm’s Tecentriq has bounced back from recent setbacks with a pivotal success in the adjuvant liver cancer setting.
You may also be interested in...
The move marks the second time since last year that Roche has withdrawn a urothelial carcinoma indication after its confirmatory trial failed to show an overall survival benefit.
Roche's pharma revenues declined in the third quarter, but the Swiss major is hoping that Tecentriq in adjuvant settings can boost future revenues – and that, just maybe, it will have a win from its Alzheimer’s candidate too.
The Roche affiliate hopes to bring subcutaneous Tecentriq to market, offering patient and clinician advantages while also beating Merck’s Keytruda and Bristol’s Opdivo to the finish line